

Clinical Trial Protocol

Iranian Registry of Clinical Trials

25 Aug 2026

Effects of lemon balm extract on glycemic criteria, lipid profile, apolipoprotein B, apolipoprotein A-1, antioxidant capacity and hs-CRP in comparison with control group in patients with type II diabetes

Protocol summary

Study aim

This study aims to investigate the effect of *Melissa officinalis* extract on glycemic status, lipid profile, apolipoprotein B, apolipoprotein A1, total antioxidant capacity and hs-CRP in patients with type II diabetes.

Design

Patients will be randomly assigned two groups. In the intervention group, patients will receive two capsules containing 350 mg *Melissa officinalis* extract per day for 3 months. Patients in the control group will receive two capsules containing 350 mg toasted flour twice daily for 3 months. Laboratory tests including glycemic status, lipid profile, apolipoprotein B, apolipoprotein A1, total antioxidant capacity and hs-CRP, also blood pressure and anthropometric indices will be measured at baseline and at the end study. Also, the dietary intakes and physical activity will be measured.

Settings and conduct

In this randomized double-blinded placebo-control clinical trial 70 patients with type 2 diabetes referring to the Iranian Diabetes Society and Institute of Endocrinology and Metabolism will be included.

Participants/Inclusion and exclusion criteria

Inclusion criteria are: Patients aged 20 to 65 years for both sexes; BMI less than 35 kg/m²; no pregnancy or lactation; TG less than 400 mg/dl; HbA1c < % 8; using oral hypoglycemic agents. Exclusion criteria are: possess of any co-disorders including cardiovascular, liver, renal, allergic and infectious diseases as well as thyroid disorders and glaucoma; taking NSAIDs drugs or estrogen and progesterone.

Intervention groups

Intervention group: Taking orally 2 capsules of 350 mg *Melissa officinalis* extract per day for 3 months. Capsules are provided in Institute of Medicinal Plants affiliated with ACECR. Placebo group: Taking orally 2 similar capsules of toasted flour.

Main outcome variables

FBS, Fasting insulin, Total antioxidant capacity, Apo A-1, Apo B, HbA1c, TG, TC, HDL-C, LDL-C, hs-CRP, Insulin resistance (HOMA-IR)

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT201701162709N41**

Registration date: **2017-05-17, 1396/02/27**

Registration timing: **prospective**

Last update: **2018-03-25, 1397/01/05**

Update count: **1**

Registration date

2017-05-17, 1396/02/27

Registrant information

Name

Farzad Shidfar

Name of organization / entity

Iran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 8862 2755

Email address

shidfar.f@iums.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice Chancellor for Research, Iran University Of Medical Sciences

Expected recruitment start date

2017-05-22, 1396/03/01

Expected recruitment end date

2017-08-23, 1396/06/01

Actual recruitment start date

2017-05-22, 1396/03/01

Actual recruitment end date

2017-11-01, 1396/08/10

Trial completion date

empty

Scientific title

Effects of lemon balm extract on glycemic criteria, lipid profile, apolipoprotein B, apolipoprotein A-1, antioxidant capacity and hs-CRP in comparison with control group in patients with type II diabetes

Public title

Effects of lemon balm extract on glycemic criteria, lipid profile, hs-CRP and antioxidant status in patients with type II diabetes

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Inclusion criteria are: Patients aged 20 to 65 years for both sexes; The body mass index less than 35 kg/m²; no pregnancy or lactation; triglycerides less than 400 mg/dl; HbA1c < % 8; using a common diabetes drug (metformin and glibenclamide). Exclusion criteria are: Lack of any co-disorders including cardiovascular, liver, renal, allergic and infectious diseases as well as thyroid disorders and glaucoma; taking non steroidal anti-inflammatory drugs (NSAIDS) or estrogen and progesterone.

Exclusion criteria:**Age**

From **20 years** old to **65 years** old

Gender

Both

Phase

N/A

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

Sample size

Target sample size: **70**

Actual sample size reached: **62**

Randomization (investigator's opinion)

Randomized

Randomization description

The patients will be categorized in two groups by random allocation.

Blinding (investigator's opinion)

Double blinded

Blinding description

The patients will be categorized into three groups by random allocation.

Placebo

Used

Assignment

Parallel

Other design features

The patients will be categorized in three groups by random allocation.

Secondary Ids

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Iran University of Medical Sciences

Street address

Iran University Of Medical Science, Hemmat highway, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1449614535

Approval date

2017-01-09, 1395/10/20

Ethics committee reference number

IR.IUMS.REC 1395.9411468001

Health conditions studied**1****Description of health condition studied**

Type 2 diabetes mellitus

ICD-10 code

E10, E11,

ICD-10 code description

Non-insulin-dependent diabetes mellitus

Primary outcomes**1****Description**

FBS

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

Enzymatic method

2**Description**

Fasting insulin

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

ELISA

3

Description

Total antioxidant capacity

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

Colorimetry (FRAP)

4

Description

Apo A-1

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

Immunoturbidimetry

5

Description

Apo B

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

Immunoturbidimetry

6

Description

HbA1c

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

High Performance Liquid Chromatography

7

Description

TG

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

Enzymatic method

8

Description

TC

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

Enzymatic method

9

Description

HDL-C

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

Enzymatic method

10

Description

LDL-C

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

Friedewald formula

11

Description

hs-CRP

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

ELISA

12

Description

Insulin resistance (HOMA-IR)

Timepoint

before the experiment and 12 weeks after intervention

Method of measurement

Formula

Secondary outcomes

1

Description

BP

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

Mercury sphygmomanometer

2

Description

Body mass index

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

Weight (kg) /height² (m²)

3

Description

Weight

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

Seca scale

4

Description

Waist circumference

Timepoint

Before the experiment and 12 weeks after intervention

Method of measurement

Elastic tape

5

Description

Physical activity

Timepoint

Before intervention and 6 and 12 weeks after intervention

Method of measurement

International Physical Activity Questionnaire

6

Description

Energy intake

Timepoint

Before intervention and 6 and 12 weeks after intervention

Method of measurement

24-hour dietary recall

Intervention groups

1

Description

Intervention group: Taking orally 2 herbal capsules of 350 mg melissa officinalis extract per day (one after Lunch and one after Dinner) for 3 months. Capsules are provided in Institute of Medicinal Plants affiliated with ACECR.

Category

Treatment - Drugs

2

Description

Placebo group: Taking orally 2 similar capsules of toasted flour per day for 3 months

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

The Institute of Endocrinology and Metabolism Research (Iran University Of Medical Sciences)

Full name of responsible person

Iraj Heidary

Street address

Endocrine and Research Center-Firozgar Education Center-Behafarin Avenue-Valiasr Square

City

Tehran

Province

Tehran

Postal code

5977146377

Phone

+98 21 8862 2755

Email

farzadshidfar@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice Chancellor for Research, Iran University Of Medical Sciences

Full name of responsible person

Dr. Seyed Ali Javad Moosavi

Street address

7th Floor, Department of Internal Medicine, Hazrat-E-Rasoul Hospital, Iran University of Medical Sciences, Niayesh St., Sattarkahn Ave, Tehran, Iran.

City

Tehran

Province

Tehran

Postal code

5977146377

Phone

+98 21 8862 2755

Email

Dr_moosavi@yahoo.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice Chancellor for Research, Iran University Of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Iran University Of Medical Science

Full name of responsible person

Farzad Shidfar

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Iran University Of Medical Science, Hemmat
highway,Tehran,Iran

City

Tehran

Province

Tehran

Postal code

59771346377

Phone

+98 21 8670 4711

Fax**Email**

shidfar.f@iums.ac.ir

Web page address

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Iran University of Medical Sciences

Full name of responsible person

Farzad Shidfar

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Iran University of medical science, Hemmat
highway,Tehran,Iran

City

Tehran

Province

Tehran

Postal code

5977146377

Phone

+98 21 8670 4711

Fax**Email**

shidfar.f@iums.ac.ir

Web page address

Person responsible for updating data

Contact**Name of organization / entity**

Iran University Of Medical Science

Full name of responsible person

Akbar Asadi

Position

MS.c student in Nutrition Science

Latest degree

Bachelor

Other areas of specialty/work

Nutrition

Street address

Iran University of medical science, Hemmat
highway,Tehran,Iran

City

Tehran

Province

Tehran

Postal code

5977146377

Phone

+98 21 8862 2755

Fax**Email**

a-m.asadi@tak.iums.ac.ir

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to
make this available

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to
make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to
make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to
make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to
make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to
make this available